Title: Metabolism of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase
Authors: Balzarini, Jan ×
Stet, L
Matsuda, A
Wiebe, L
Knauss, E
De Clercq, Erik #
Issue Date: 4-Jul-1998
Host Document: Advances in Experimental Medicine and Biology vol:431 pages:723-8
Conference: Proceedings of the 9th International/6th Eropean Joint Symposium on Purine & Pyrimidine Metabolism in Man location:Gmunden, Austria date:1-7 June 1997
Abstract: The cytostatic agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) causes a rapid and marked inhibition of inosinate (IMP) dehydrogenase activity in intact tumor cells. [3H]EICAR is metabolised in L1210 cells to its 5'-mono-, 5'-di- and 5'-triphosphate in a concentration-dependent manner. The metabolites accumulate proportionally with the initial extracellular EICAR concentrations (ranging from 0.25 to 200 microM). The nicotinamide adenine dinucleotide (NAD) analogue of EICAR, designated EAD, also accumulates within the cells and becomes the major metabolite after 48 hr incubation with 5 microM [3H]EICAR. EAD has a markedly longer intracellular half-life than EICAR 5'-mono-, 5'-di- and 5'-triphosphate. An additional EICAR metabolite elutes on an anion exchange Partisphere SAX HPLC chromatogram between EICAR 5'-di- and 5'-triphosphate. Its intracellular levels are approximately 10-fold lower than those of EAD and the nature of this metabolite has still to be identified. The differential role of EAD and EICAR 5'-monophosphate in the inhibition of IMP dehydrogenase is currently under investigation.
ISSN: 0065-2598
Publication status: published
KU Leuven publication type: IC
Appears in Collections:Laboratory of Virology and Chemotherapy (Rega Institute)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science